← Back to Search

Unknown

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

Phase 2
Waitlist Available
Research Sponsored by Goldfinch Bio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests the long-term safety of GFB-887 in patients with specific kidney diseases that don't respond to usual treatments. Patients will take the medication daily, and its safety and effectiveness will be monitored over an extended period.

Eligible Conditions
  • Osmotic Nephrosis
  • Kidney Disease
  • Kidney Stones
  • Focal Segmental Glomerulosclerosis
  • Nephritis
  • Post-Infectious Glomerulonephritis
  • Nephrotic Syndrome
  • Glomerulonephritis
  • Glomerulosclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence and severity of adverse events
Secondary study objectives
Changes in estimated glomerular filtration rate (eGFR) including slope
Percent reduction in urine protein:creatinine ratio (UPCR) from baseline
Proportion of participants achieving complete remission status
+9 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 200 mg Dose CohortExperimental Treatment1 Intervention
Participants who received GFB-887 or placebo in GFB-887-201 will receive GFB-887 at a daily dose level of 200 mg regardless of original dose level.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GFB-887
2019
Completed Phase 1
~70

Find a Location

Who is running the clinical trial?

Goldfinch Bio, Inc.Lead Sponsor
4 Previous Clinical Trials
225 Total Patients Enrolled
~7 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top